Secukinumab Injection Market
The market for Secukinumab Injection was estimated at $2.5 billion in 2024; it is anticipated to increase to $4.9 billion by 2030, with projections indicating growth to around $8.5 billion by 2035.
Report Summary
Market Data
Methodology
Table of Contents
Global Secukinumab Injection Market Outlook
Revenue, 2024
$2.5B
Forecast, 2034
$7.6B
CAGR, 2025 - 2034
11.8%
The Secukinumab Injection industry revenue is expected to be around $2.8 billion in 2025 and expected to showcase growth with 11.8% CAGR between 2025 and 2034. The market continues to gain strong commercial and clinical importance due to the increasing prevalence of chronic autoimmune and inflammatory disorders worldwide. Rising diagnosis rates of conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis are significantly contributing to product adoption across hospital and specialty care settings. Growing awareness regarding biologic therapies, combined with improvements in patient access to advanced immunomodulatory treatments, is further strengthening market expansion. In addition, favorable reimbursement support in developed healthcare systems and continuous investments in targeted monoclonal antibody research are enhancing the long term relevance of secukinumab injections in modern inflammatory disease management strategies.
Secukinumab injection is a biologic therapy developed as an interleukin 17A inhibitor designed to reduce inflammatory responses associated with autoimmune diseases. It is widely utilized for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and other inflammatory musculoskeletal conditions. The therapy is recognized for its targeted mechanism of action, rapid symptom relief, and ability to improve long term disease management outcomes with relatively lower systemic side effects compared to traditional immunosuppressive therapies. Increasing physician preference for precision biologics and expanding approvals for additional inflammatory indications are driving demand across global healthcare markets. Recent trends include the development of self injectable formulations, rising adoption of home based treatment approaches, and increasing clinical studies focused on combination biologic therapies to enhance therapeutic efficiency and patient adherence.
Market Key Insights
The Secukinumab Injection market is projected to grow from $2.5 billion in 2024 to $7.6 billion in 2034. This represents a CAGR of 11.8%, reflecting rising demand across Psoriasis Treatment, Ankylosing Spondylitis Management, and Psoriatic Arthritis.
Novartis AG, Johnson & Johnson Services Inc., Pfizer Inc. are among the leading players in this market, shaping its competitive landscape.
U.S. and Germany are the top markets within the Secukinumab Injection market and are expected to observe the growth CAGR of 8.6% to 12.4% between 2024 and 2030.
Emerging markets including Brazil, South Africa and Philippines are expected to observe highest growth with CAGR ranging between 11.3% to 14.8%.
Transition like Transition From Conventional Immunosuppressants Toward Targeted Biologic Autoimmune Therapies is expected to add $584 million to the Secukinumab Injection market growth by 2030.
The Secukinumab Injection market is set to add $5.1 billion between 2024 and 2034, with manufacturer targeting Rheumatoid Arthritis Treatment & Ankylosing Spondylitis Treatment Application projected to gain a larger market share.
With Rising prevalence of autoimmune disorders, and technological Advancements, Secukinumab Injection market to expand 205% between 2024 and 2034.
Opportunities in the Secukinumab Injection
Growing regulatory approvals for pediatric autoimmune therapies are also creating strong opportunities for secukinumab injection manufacturers in developed healthcare markets. Specialty dermatology centers in the United States, Germany, and Japan are increasingly adopting biologic therapies for children with moderate to severe plaque psoriasis who show limited response to conventional treatments. Prefilled pen and low dose formulations are expected to witness higher demand because they improve administration convenience and treatment adherence among younger patients. Increasing parental awareness regarding targeted biologic therapies and rising investments in pediatric autoimmune research are further strengthening growth potential within this relatively underpenetrated treatment segment globally.
Growth Opportunities in North America and Asia Pacific
North America represents a leading regional market for secukinumab injections due to the high prevalence of autoimmune disorders, advanced biologic therapy adoption, and strong healthcare reimbursement systems. The United States accounts for the largest share, supported by increasing diagnosis rates of plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis. Major pharmaceutical companies are actively expanding immunology portfolios and strengthening partnerships with specialty clinics and hospital networks to improve patient access. Rising demand for self injectable biologic therapies and homecare treatment models is creating significant growth opportunities for prefilled syringes and auto injector formats. Competitive intensity remains high as biologic manufacturers and biosimilar developers compete through pricing strategies, patient assistance programs, and product differentiation. Additionally, growing investments in digital health integration and remote patient monitoring services are supporting long term market expansion across outpatient autoimmune disease management platforms in the region.
Asia Pacific is emerging as a rapidly expanding market for secukinumab injections due to improving healthcare infrastructure, rising autoimmune disease awareness, and increasing biologic therapy accessibility. Countries such as China, India, Japan, and South Korea are witnessing strong growth in rheumatology and dermatology treatment demand, supported by urbanization and expanding healthcare insurance coverage. Multinational pharmaceutical companies are increasing regional investments and forming strategic collaborations with local distributors and specialty hospitals to strengthen biologic drug penetration. Hospital based biologic administration currently dominates the market, although homecare injectable therapies are gradually gaining popularity in developed Asian economies. Competitive pressure is intensifying as regional pharmaceutical firms and biosimilar manufacturers enter the autoimmune therapeutics segment with lower cost alternatives. Additionally, government healthcare modernization initiatives and expanding specialty pharmacy networks are creating substantial opportunities for long term secukinumab market growth across Asia Pacific healthcare systems.
Market Dynamics and Supply Chain
01
Driver: Rising Autoimmune Disease Prevalence and Expanding Biologic Therapy Adoption Across Healthcare Systems
The increasing prevalence of autoimmune and chronic inflammatory disorders is also a major growth factor supporting the secukinumab injection market. Rising cases of plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis are also creating long term demand for targeted immunology therapies, particularly in aging populations and urban regions with higher inflammatory disease incidence. Simultaneously, the expanding adoption of biologic therapies across healthcare systems is also accelerating market penetration. Hospitals and specialty clinics are also increasingly preferring biologics due to their superior efficacy and precision compared to traditional systemic drugs. Technological improvements in recombinant monoclonal antibody production and enhanced cold chain distribution systems are also also strengthening product availability globally. In addition, favorable reimbursement support for advanced biologics in developed economies is also encouraging greater patient access to secukinumab based treatment solutions.
Technological innovation in self administration devices is also significantly driving demand for secukinumab injections worldwide. Pharmaceutical manufacturers are also increasingly introducing user friendly prefilled pens and auto injector systems designed to simplify biologic drug delivery for chronic disease patients. These advanced injection systems improve dosing accuracy, reduce administration discomfort, and support home based treatment convenience. The growing preference for self managed therapies among patients with autoimmune disorders is also strengthening adoption rates, especially in outpatient care settings. Additionally, digital health integration and patient monitoring technologies are also improving adherence tracking and therapy continuity. This trend is also helping healthcare providers deliver efficient long term disease management while reducing hospital dependency and treatment administration burdens.
02
Restraint: High Biologic Therapy Costs And Limited Reimbursement Reducing Patient Treatment Accessibility
The high treatment cost associated with secukinumab injections remains a major restraint limiting broader market penetration, particularly in low and middle income countries. Biologic therapies require complex manufacturing processes, specialized storage systems, and long term treatment schedules, significantly increasing overall healthcare expenditure. In several developing healthcare markets, inadequate insurance coverage and restrictive reimbursement policies discourage patient adoption of premium biologic drugs. For example, many patients continue relying on lower cost conventional immunosuppressants despite lower therapeutic effectiveness. This pricing challenge reduces treatment continuity, limits prescription volumes in price sensitive regions, and slows overall market revenue growth for manufacturers competing in the autoimmune therapeutics sector.
03
Opportunity: Rising Homecare Biologic Administration Demand Among Chronic Autoimmune Disorder Patients Globally and Increasing Autoimmune Disease Diagnosis Rates Across Emerging Asia Pacific Healthcare Markets
The rapid shift toward home based biologic therapy administration is generating new growth opportunities for secukinumab injections worldwide. Patients with chronic inflammatory diseases are increasingly preferring self injectable biologics that reduce hospital visits and support long term treatment flexibility. Auto injector and prefilled syringe formats are anticipated to experience the fastest growth due to rising consumer demand for user friendly and minimally invasive drug delivery systems. Pharmaceutical companies are also collaborating with digital health providers to improve remote patient monitoring and adherence tracking. This transition is expected to expand outpatient treatment adoption, particularly across North America and Western Europe healthcare markets.
Emerging healthcare economies in Asia Pacific are presenting substantial untapped opportunities for secukinumab injection manufacturers. Countries including India, China, and South Korea are witnessing increasing diagnosis rates of psoriatic arthritis and ankylosing spondylitis because of improving healthcare access and growing awareness regarding autoimmune disorders. Hospital administered biologic therapies are projected to dominate regional demand as tertiary care centers continue expanding advanced immunology treatment capabilities. Strategic collaborations between multinational pharmaceutical companies and regional healthcare providers are further supporting biologic therapy penetration. Additionally, improvements in healthcare insurance coverage and specialty pharmacy distribution networks are expected to accelerate secukinumab adoption across urban patient populations.
04
Challenge: Growing Biosimilar Competition Creating Pricing Pressure Across Autoimmune Disease Treatment Markets
The emergence of biosimilar therapies is increasingly challenging the revenue expansion of branded secukinumab injections worldwide. Pharmaceutical companies are investing heavily in developing lower cost biosimilar alternatives targeting inflammatory and autoimmune disorders, intensifying competitive pressure in the biologics market. Healthcare providers and insurers are gradually encouraging biosimilar adoption to reduce treatment expenditure and optimize healthcare budgets. For instance, hospitals in several European markets are prioritizing cost effective biologic substitutes during procurement processes. This trend is creating downward pricing pressure on premium branded therapies, reducing manufacturer profit margins and influencing physician prescribing behavior, particularly in highly regulated healthcare systems with aggressive cost containment strategies.
Supply Chain Landscape
1
Raw Material Suppliers
DuPontBayer AG
2
API Production
Roche AGNovartis AG
3
Formulation Development
Biogen IncJohnson & Johnson
4
End User Industry
PharmaceuticalDermatologyRheumatology
1
Raw Material Suppliers
DuPontBayer AG
2
API Production
Roche AGNovartis AG
3
Formulation Development
Biogen IncJohnson & Johnson
4
End User Industry
PharmaceuticalDermatologyRheumatology
Use Cases of Secukinumab Injection in Psoriasis Treatment & Ankylosing Spondylitis Management
Psoriasis Treatment : Secukinumab injection is widely used for moderate to severe plaque psoriasis treatment, particularly among adult patients requiring long term biologic therapy. The injection mainly targets interleukin 17A, a cytokine strongly associated with inflammatory skin disorders. Hospitals, dermatology clinics, and specialty care centers are the primary end users utilizing prefilled syringes and auto injector formulations for convenient administration. Its ability to provide rapid skin clearance, reduce plaque formation, and improve patient quality of life has increased its adoption globally. The therapy is especially beneficial for patients unresponsive to conventional systemic drugs, as it delivers targeted immune modulation with sustained efficacy and lower relapse frequency.
Ankylosing Spondylitis Management : In ankylosing spondylitis management, secukinumab injection is commonly prescribed to control chronic spinal inflammation and joint stiffness. Rheumatology clinics and specialty hospitals represent the major end users due to the need for continuous monitoring and long term disease management. The biologic formulation is preferred for patients with inadequate response to tumor necrosis factor inhibitors or nonsteroidal anti inflammatory drugs. By inhibiting interleukin 17A activity, secukinumab helps reduce pain, improve mobility, and slow structural joint damage progression. The therapy has gained significant clinical acceptance because of its effectiveness in enhancing physical function while minimizing disease flare ups and improving patient comfort during long duration treatment cycles.
Psoriatic Arthritis : Secukinumab injection is extensively utilized in psoriatic arthritis treatment for patients experiencing both joint inflammation and psoriasis symptoms simultaneously. Rheumatologists and integrated autoimmune disease centers are the primary end users adopting this biologic therapy for comprehensive disease control. Prefilled pen and syringe formats are frequently used to support self administration and improve treatment adherence. The injection works by suppressing interleukin 17A driven inflammation, helping reduce swollen joints, tenderness, and skin lesions. Its dual therapeutic action offers a major advantage for patients with overlapping dermatological and musculoskeletal complications. Increasing awareness regarding targeted biologic therapies and the growing prevalence of autoimmune disorders continue to support demand for secukinumab in psoriatic arthritis applications.
Impact of Industry Transitions on the Secukinumab Injection Market
As a core segment of the Pharmaceutical industry,
the Secukinumab Injection market develops in line with broader industry shifts.
Over recent years, transitions such as Transition From Conventional Immunosuppressants Toward Targeted Biologic Autoimmune Therapies and Transition From Hospital Based Administration Toward Homecare Biologic Treatment Models have redefined priorities
across the Pharmaceutical sector,
influencing how the Secukinumab Injection market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Transition From Conventional Immunosuppressants Toward Targeted Biologic Autoimmune Therapies
The secukinumab injection market is supporting a broader industry transition from traditional immunosuppressive drugs toward targeted biologic therapies for autoimmune disease management. Healthcare providers are increasingly preferring biologic injections because they offer more precise inflammatory control and improved long term patient outcomes. This transition is significantly influencing the dermatology and rheumatology industries, where specialty clinics are expanding biologic treatment programs and investing in advanced patient monitoring services. Pharmaceutical companies are also shifting research investments toward monoclonal antibody development, reducing dependence on older systemic therapies. As a result, demand for specialty biologics distribution, cold chain logistics, and personalized autoimmune treatment solutions continues to strengthen globally.
02
Transition From Hospital Based Administration Toward Homecare Biologic Treatment Models
The growing adoption of secukinumab injections is accelerating the transition from hospital centered biologic administration to home based treatment models. Patients with chronic autoimmune disorders increasingly prefer self injectable therapies that reduce repeated hospital visits and support convenient long term disease management. This shift is creating strong demand within the home healthcare and digital patient monitoring industries. For example, pharmaceutical companies are partnering with telehealth providers and specialty pharmacies to improve treatment adherence and remote patient support. The transition is also encouraging innovation in auto injector devices and connected healthcare platforms, while outpatient care providers are adapting services to accommodate the rising preference for decentralized biologic therapy administration.